These findings suggest that improved chemotherapy with nanosystems and the RANK/RANKL pathway inhibitors can inhibit the interaction between tumor cells and the BME components and balance the activity of osteoblasts and osteoclasts (139). Here, TNFSF11 is linked to neoplasm.